HF
REGN icon

HRT Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

HRT Financial’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.8M Buy
19,100
+11,500
+151% +$8.8M 0.04% 462
2025
Q4 		$5.87M Buy
+7,600
New +$5.16M 0.02% 701
2023
Q2 		– Sell
-600
Closed -$493K – 3131
2023
Q1 		$493K Buy
+600
New +$453K 0.01% 1395

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HRT Financial's REGN Position: Q4 2025 in Review

HRT Financial sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 98,849 shares — an estimated $67.1M sold.

HRT Financial first reported a position in REGN in Q3 2015 and held it in 17 quarters. The position peaked at $55.6M in Q3 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • HRT Financial reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 98,849 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $67.1M.
  • HRT Financial first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 17 quarters.
  • HRT Financial's Regeneron Pharmaceuticals position peaked at $55.6M in Q3 2025.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.